Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.49 |
| ▸ | MAPK14 | Q16539 | 16/20 | 0.48 |
| ▸ | MAPK13 | O15264 | 6/20 | 0.48 |
| ▸ | MAPK12 | P53778 | 6/20 | 0.48 |
| ▸ | MAPK11 | Q15759 | 6/20 | 0.48 |
| ▸ | DDR2 | Q16832 | 1/20 | 0.44 |
| ▸ | MAPK9 | P45984 | 2/20 | 0.44 |
| ▸ | CDK8 | P49336 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3294801 | 0.92 | MAPK14 (0.52) | HPGDNTRK1MAPK14MAPK13MAPK12 | |
| SCHEMBL3295711 | 0.90 | NTRK1 (0.53) | HPGDNTRK1MAPK14MAPK13MAPK12 | |
| SCHEMBL13296921 | 0.90 | MAPK14 (0.56) | MAPK14MAPK13MAPK12MAPK11DDR2 | |
| SCHEMBL3297689 | 0.89 | MAPK14 (0.57) | HPGDNTRK1MAPK14MAPK13MAPK12 | |
| SCHEMBL3295881 | 0.88 | MAPK14 (0.53) | HPGDNTRK1MAPK14MAPK13MAPK12 | |
| SCHEMBL3295310 | 0.88 | HPGD (0.51) | HPGDNTRK1MAPK14MAPK13MAPK12 | |
| SCHEMBL3297342 | 0.84 | NTRK1 (0.47) | HPGDNTRK1MAPK14MAPK13MAPK12 | |
| SCHEMBL3295754 | 0.83 | HPGD (0.49) | HPGDNTRK1MAPK14MAPK13MAPK12 | |
| SCHEMBL3300827 | 0.83 | MAPK14 (0.54) | HPGDNTRK1MAPK14MAPK13MAPK12 | |
| SCHEMBL3299366 | 0.82 | MAPK14 (0.72) | NTRK1MAPK14MAPK13MAPK12MAPK11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7737283-B2 | Anti-inflammatory medicaments | DECIPHERA PHARMACEUTICALS, LLC (US) | 2010-06-15 | — | — | US | disclosed |
| US-7737283-B2 | Anti-inflammatory medicaments | DECIPHERA PHARMACEUTICALS, LLC (US) | 2010-06-15 | — | — | US | disclosed |
| US-7737283-B2 | Anti-inflammatory medicaments | DECIPHERA PHARMACEUTICALS, LLC (US) | 2010-06-15 | — | — | US | disclosed |
| US-7531566-B2 | Anti-inflammatory medicaments | DECIPHERA PHARMACEUTICALS, LLC (US) | 2009-05-12 | — | — | US | disclosed |
| US-7531566-B2 | Anti-inflammatory medicaments | DECIPHERA PHARMACEUTICALS, LLC (US) | 2009-05-12 | — | — | US | disclosed |
| US-7531566-B2 | Anti-inflammatory medicaments | DECIPHERA PHARMACEUTICALS, LLC (US) | 2009-05-12 | — | — | US | disclosed |
| US-20090105230-A1 | Anti-inflammatory medicaments | FLYNN DANIEL L | 2009-04-23 | — | — | US | disclosed |
| US-20090105230-A1 | Anti-inflammatory medicaments | FLYNN DANIEL L | 2009-04-23 | — | — | US | disclosed |
| US-20090105230-A1 | Anti-inflammatory medicaments | FLYNN DANIEL L | 2009-04-23 | — | — | US | disclosed |
| US-20090075986-A1 | Anti-inflammatory medicaments | DECIPHERA PHARMACEUTICALS, LLC | 2009-03-19 | — | — | US | disclosed |
| US-20070191336-A1 | p38 kinase inhibitors | DECIPHERA PHARMACEUTICALS, LLC | 2007-08-16 | — | — | US | disclosed |
| EP-1773784-A2 | ANTI-INFLAMMATORY MEDICAMENTS | Deciphera Pharmaceuticals, LLC (US) | 2007-04-18 | — | — | EP | disclosed |
| US-7202257-B2 | Anti-inflammatory medicaments | DECIPHERA PHARMACEUTICALS, LLC (US) | 2007-04-10 | — | — | US | disclosed |
| US-7202257-B2 | Anti-inflammatory medicaments | DECIPHERA PHARMACEUTICALS, LLC (US) | 2007-04-10 | — | — | US | disclosed |
| US-7202257-B2 | Anti-inflammatory medicaments | DECIPHERA PHARMACEUTICALS, LLC (US) | 2007-04-10 | — | — | US | disclosed |
| US-20070037808-A1 | p38 kinase inhibitors | DECIPHERA PHARMACEUTICALS, LLC | 2007-02-15 | — | — | US | disclosed |
| US-20070037808-A1 | p38 kinase inhibitors | DECIPHERA PHARMACEUTICALS, LLC | 2007-02-15 | — | — | US | disclosed |
| US-20070037808-A1 | p38 kinase inhibitors | DECIPHERA PHARMACEUTICALS, LLC | 2007-02-15 | — | — | US | disclosed |
| WO-2006014290-A2 | ANTI-INFLAMMATORY MEDICAMENTS | DECIPHERA PHARMACEUTICALS, LLC (US) | 2006-02-09 | — | — | WO | disclosed |
| US-20050288286-A1 | Anti-inflammatory medicaments | DECIPHERA PHARMACEUTICALS, LLC | 2005-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105230-A1 | Anti-inflammatory medicaments | MIF, PTGES2, TNF | HPGD 816/4885NTRK1 3381/4885MAPK14 56/4885 |
| US-20090075986-A1 | Anti-inflammatory medicaments | MIF, PTGES2, TNF | HPGD 816/4885NTRK1 3381/4885MAPK14 56/4885 |
| US-20070037808-A1 | p38 kinase inhibitors | MAPK1, MAP3K8, MAP3K1 | HPGD 1844/4885NTRK1 892/4885MAPK14 29/4885 |
| US-20050288286-A1 | Anti-inflammatory medicaments | MIF, PTGES2, TNF | HPGD 816/4885NTRK1 3381/4885MAPK14 56/4885 |
| US-20070191336-A1 | p38 kinase inhibitors | MAPK1, MAP3K8, MAP3K1 | HPGD 1844/4885NTRK1 892/4885MAPK14 29/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.